BEGIN:VCALENDAR
PRODID:-//github.com/rianjs/ical.net//NONSGML ical.net 4.0//EN
VERSION:2.0
BEGIN:VEVENT
DESCRIPTION:The antifibrotic field is at an inflection point: Madrigal’s R
 esmetirom secured the first-ever MASH approval in 2024\, Boehringer’s ner
 andomilast hit its Phase 3 endpoint in IPF\, and pharma giants like Lilly
  and GSK are investing billions in fibrosis pipelines. Yet\, with GLP-1s 
 reshaping metabolic disease treatment and organ-specific challenges persi
 sting\, developers must now prove differentiation\, whether through novel
  targets\, biomarker strategies\, or pan-fibrotic mechanisms.\n\nTackle t
 hese shared challenges alongside 80+ leaders from Pfizer\, Novartis\, Gil
 ead Sciences\, and pioneering biotechs at the 9th Antifibrotic Drug Devel
 opment Summit - the only cross-fibrosis industry summit bridging discover
 y to Phase 2\, across IPF\, MASH\, kidney\, cardiac\, and systemic sclero
 sis fibrosis.\n\n&nbsp\;\n\nURLs:Brochure: https://go.evvnt.com/3178913-0
 ?pid=185&nbsp\;Tickets: https://go.evvnt.com/3178913-3?pid=185&nbsp\;\n\n
 Date and Time: Mon\, 17 Nov 2025 08:30 - Wed\, 19 Nov 2025 15:30\n\nVenue
  details: Wyndham Boston Beacon Hill\, 5 Blossom Street\, Boston\, Massac
 husetts\, 02114\, United States\n\nCategory: Conferences | Science\, Heal
 th &amp\; Medicine | Pharmaceuticals | Drug Development\n\nPrices:Academi
 c - Conference Only: USD 2599.00\,Academic - Conference + Workshop Day: U
 SD 3597.00\,Solution Provider Pricing - Conference Only: USD 3699.00\,Sol
 ution Provider Pricing - Conference + Workshop Day: USD 5097.00\,Drug Dev
 eloper Pricing - Conference Only: USD 2999.00\,Drug Developer Pricing - C
 onference + Workshop Day: USD 4197.00\n\nSpeakers: Ahmed Mousa\, Chief Ex
 ecutive Officer\, Vicore Pharma\, Anna Zagorska\, Director\, Inflammation
  and Fibrosis\, Gilead Sciences\, Caroline Phillips\, Chief Scientific Of
 ficer\, RedX Pharma\, Daniel Wilcock\, Principal Translational Scientist\
 , RedX Pharma\, Dori Thomas-Karyat\, Chief Executive Officer\, Synthis Th
 erapeutics\, Gary Sweeney\, President and Professor\, Toronto BioScience 
 Inc and York University\, Henrik Landgren\, Scientific Director\, Precisi
 on Medicine Immunology and Fibrosis\, Abbvie\, Jeffrey Bornstein\, Chief 
 Medical Officer\, Mediar Therapeutics\, Jen-Chieh Chuang\, Program\, Tran
 slational Medicine and Biomarker Lead\, Takeda Pharmaceutical\, John Nico
 sia\, Chief Operating Officer\, Vasarya Therapeutics\, Katie McCauley\, D
 irector and Portfolio Strategy and Fibrosis Research Lead\, Novartis\, Ke
 vin Hart\, Associate Research Fellow\, Scientific Director\, Fibrosis Exp
 loratory Biology and Drug Discovery Group\, Pfizer\, Lee Borthwick\, Chie
 f Operating Officer\, FibroFind\, Leslie Nangle\, Vice President\, Resear
 ch\, aTyr Pharma Inc.\, Louise Goksøyr\, Project Lead and Scientist\, Ada
 ptVac\, Mehrsa Mehrabi\, Senior Scientist\, Viscient Biosciences\, Min Lu
 \, Executive Director\, Eli Lilly and Co.\, Rebecca Taub\, Chief Executiv
 e Officer\, Madrigal Pharmaceuticals\, Remi Laberge\, CTO\, Arda Therapeu
 tics\, Rob Menzies\, Senior Director\, AstraZeneca\, Rui Wu\, Chief Offic
 er \,Senior Vice President and Head of Research and Preclinical \,Chemist
 ry\, Manufacturing and Controls\, Graviton BioScience\, Sydney Montesi\, 
 Pulmonary and Critical Care Medicine Physician\, Massachusetts General Ho
 spital\, Vipin Kumar\, Co-Founder and Chief Scientific Officer\, GRI Bio\
 , Yury Popov\, Co-Director\, Pathogens Immunity and Inflammation Translat
 ional Hub and Associate Professor\, Medicine\, Beth Israel Deaconess Medi
 cal Center\n
DTEND:20251119T153000
DTSTAMP:20260512T220335Z
DTSTART:20251117T083000
LOCATION:Wyndham Boston Beacon Hill\, 5\, Blossom Street\, Boston\, Massac
 husetts\, 02114\,
SEQUENCE:0
SUMMARY:The antifibrotic field is at an inflection point: Madrigal’s Resme
 tirom secured the first-ever MASH approval in 2024\, Boehringer’s nerando
 milast hi...
UID:01fa6f99-76f9-4790-8b92-91d89d503d60
END:VEVENT
END:VCALENDAR